Anti-PEG immunity: Emergence, characteristics, and unaddressed questions

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 7, Issue 5, 2015, Pages 655-677

  Yang, Qi ^a   Lai, Samuel K ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b USA and North Carolina State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES; FUNCTIONAL POLYMERS; T-CELLS;

ACCELERATED BLOOD CLEARANCES; CIRCULATION TIME; CLINICAL TRIAL; HYDROPHILIC POLYMERS; IMMUNE RESPONSE; INCIDENCE RATE; MEMORY IMMUNE RESPONSE; RESEARCH GROUPS;

IMMUNE SYSTEM;

ALPHA POLYETHYLENE GLYCOL ANTIBODY; ANTIBODY; ASPARAGINASE MACROGOL; EPITOPE; IMMUNOGLOBULIN G; MACROGOL; POLYETHYLENE GLYCOL ANTIBODY; UNCLASSIFIED DRUG; URATE OXIDASE; MACROGOL DERIVATIVE;

ADAPTIVE IMMUNITY; ARTICLE; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; INCIDENCE; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA CLEARANCE; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; CHEMICAL PHENOMENA; CHEMISTRY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNITY; IMMUNOLOGY;

ANIMALS; ANTIBODIES; CHEMICAL PHENOMENA; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNITY; POLYETHYLENE GLYCOLS;

EID: 84937800081     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1339     Document Type: Article

References (99)

1. Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. WIREs Nanomed Nanobiotechnol 2012, 4:219-233.
2. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10:1451-1458.
3. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011, 6:715-728.
4. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2:214-221.
5. Zahr AS, Davis CA, Pishko MV. Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol). Langmuir 2006, 22:8178-8185.
6. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990, 268:235-237.
7. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 2000, 292:1071-1079.
8. Abu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release 2013, 172:38-47.
9. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 2007, 119:236-244.
10. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 2012, 9:1319-1323.
11. Armstrong JK. The occurence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). In: Veronese FM, ed. PEGylated Protein Drugs: Basic Science and Clinical Applications. Basel: Birkhäuser; 2009, 147-168.
12. Tirosh O, Barenholz Y, Katzhendler J, Priev A. Hydration of polyethylene glycol-grafted liposomes. Biophys J 1998, 74:1371-1379.
13. Branca C, Magazù S, Maisano G, Migliardo F, Migliardo P, Romeo G. Hydration study of PEG/water mixtures by quasi elastic light scattering, acoustic and rheological measurements. J Phys Chem B 2002, 106:10272-10276.
14. Jeon SI, Lee LH, Andrade JD, De Gennes PG. Protein-surface interactions in the presence of polyethylene oxide. I. Simplified theory. J Colloid Interf Sci 1991, 142:149-158.
15. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991, 1070:187-192.
16. Needham D, McIntosh TJ, Lasic DD. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta 1992, 1108:40-48.
17. Sharma S, Johnson RW, Desai TA. XPS and AFM analysis of antifouling PEG interfaces for microfabricated silicon biosensors. Biosens Bioelectron 2004, 20:227-239.
18. Damodaran VB, Fee CJ, Ruckh T, Popat KC. Conformational studies of covalently grafted poly(ethylene glycol) on modified solid matrices using X-ray photoelectron spectroscopy. Langmuir 2010, 26:7299-7306.
19. Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006, 27:4356-4373.
20. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009, 61:158-171.
21. Nance EA, Woodworth GF, Sailor KA, Shih TY, Xu Q, Swaminathan G, Xiang D, Eberhart C, Hanes J. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med 2012, 4:149ra119.
22. de Gennes PG. Conformation of polymers attached to an interface. Macromolecules 1980, 13:1069-1075.
23. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307:93-102.
24. Walkey CD, Olsen JB, Guo H, Emili A, Chan WC. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc 2012, 134:2139-2147.
25. Yang Q, Jones SW, Parker CL, Zamboni WC, Bear JE, Lai SK. Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. Mol Pharm 2014, 11:1250-1258.
26. Perry JL, Reuter KG, Kai MP, Herlihy KP, Jones SW, Luft JC, Napier M, Bear JE, DeSimone JM. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett 2012, 12:5304-5310.
27. Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 1983, 70:124-131.
28. Sherman MR, Williams LD, Sobczyk MA, Michaels SJ, Saifer MG. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug Chem 2012, 23:485-499.
29. Wunderlich DA, Macdougall M, Mierz DV, Toth JG, Buckholz TM, Lumb KJ, Vasavada H. Generation and characterization of a monoclonal IgG antibody to polyethylene glycol. Hybridoma (Larchmt) 2007, 26:168-172.
30. Shimizu T, Ichihara M, Yoshioka Y, Ishida T, Nakagawa S, Kiwada H. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M Response. Biol Pharm Bull 2012, 35:1336-1342.
31. Cheng TL, Wu PY, Wu MF, Chern JW, Roffler SR. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug Chem 1999, 10:520-528.
32. Moghimi SM, Gray T. A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats. Clin Sci (Lond) 1997, 93:371-379.
33. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 2007, 122:349-355.
34. Judge A, McClintock K, Phelps JR, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006, 13:328-337.
35. Ichihara M, Shimizu T, Imoto A, Hashiguchi Y, Uehara Y, Ishida T, Kiwada H. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 2011, 3:1-11.
36. Ishida T, Masuda K, Ichikawa T, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm 2003, 255:167-174.
37. Xu H, Ye F, Hu M, Yin P, Zhang W, Li Y, Yu X, Deng Y. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection. Drug Deliv 2014, 1-10. doi: 10.3109/10717544.2014.885998.
38. Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 2006, 112:15-25.
39. Ishida T, Ichihara M, Wang X, Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release 2006, 115:243-250.
40. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 2001, 298:607-612.
41. Kaminskas LM, McLeod VM, Porter CJ, Boyd BJ. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J Pharm Sci 2011, 100:5069-5077.
42. Sroda K, Rydlewski J, Langner M, Kozubek A, Grzybek M, Sikorski AF. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett 2005, 10:37-47.
43. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther 2005, 312:1020-1026.
44. Shiraishi K, Hamano M, Ma H, Kawano K, Maitani Y, Aoshi T, Ishii KJ, Yokoyama M. Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon. J Control Release 2013, 165:183-190.
45. Taguchi K, Urata Y, Anraku M, Watanabe H, Kadowaki D, Sakai H, Horinouchi H, Kobayashi K, Tsuchida E, Maruyama T, et al. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice. Drug Metab Dispos 2009, 37:2197-2203.
46. Yang Q, Ma Y, Zhao Y, She Z, Wang L, Li J, Wang C, Deng Y. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. Int J Nanomedicine 2013, 8:1257-1268.
47. Suzuki T, Ichihara M, Hyodo K, Yamamoto E, Ishida T, Kiwada H, Ishihara H, Kikuchi H. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Int J Pharm 2012, 436:636-643.
48. Li C, Cao J, Wang Y, Zhao X, Deng C, Wei N, Yang J, Cui J. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species. J Pharm Sci 2012, 101:3864-3876.
49. Zhao Y, Wang C, Wang L, Yang Q, Tang W, She Z, Deng Y. A frustrating problem: accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in rats. Eur J Pharm Biopharm 2012, 81:506-513.
50. Zhao Y, Wang L, Yan M, Ma Y, Zang G, She Z, Deng Y. Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. Int J Nanomedicine 2012, 7:2891-2900.
51. Wang C, Cheng X, Sui Y, Luo X, Jiang G, Wang Y, Huang Z, She Z, Deng Y. A noticeable phenomenon: Thiol terminal PEG enhances the immunogenicity of PEGylated emulsions injected intravenously or subcutaneously into rats. Eur J Pharm Biopharm 2013, 85:744-751.
52. Saadati R, Dadashzadeh S, Abbasian Z, Soleimanjahi H. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug. Pharm Res 2013, 30:985-995.
53. Ishihara T, Takeda M, Sakamoto H, Kimoto A, Kobayashi C, Takasaki N, Yuki K, Tanaka K, Takenaga M, Igarashi R, et al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res 2009, 26:2270-2279.
54. Zhang C, Fan K, Ma X, Wei D. Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase. PLoS One 2012, 7:e39659.
55. Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release 2003, 88:35-42.
56. Bendas G, Rothe U, Scherphof GL, Kamps JA. The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes. Biochim Biophys Acta 2003, 1609:63-70.
57. Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release 2005, 105:305-317.
58. Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem 2000, 11:258-266.
59. Ishida T, Atobe K, Wang X, Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J Control Release 2006, 115:251-258.
60. Ishida T, Kashima S, Kiwada H. The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J Control Release 2008, 126:162-165.
61. Kawanishi M. Comprehensive analysis of PEGylated liposome-associated proteins relating to the accelerated blood clearance phenomenon by combination with shotgun analysis and conventional methods. Biotechnol Appl Biochem 2014. doi: 10.1002/bab.1291.
62. Guidance for industry: immunogenicity assessment for therapeutic protein products. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegula-toryInformation/Guidances/UCM338856.pdf. (Accessed October 2, 2014).
63. Koide H, Asai T, Hatanaka K, Akai S, Ishii T, Kenjo E, Ishida T, Kiwada H, Tsukada H, Oku N. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int J Pharm 2010, 392:218-223.
64. Cerutti A, Cols M, Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 2013, 13:118-132.
65. Shimizu T, Ishida T, Kiwada H. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology 2012, 218:725-732.
66. Sha Z, Compans RW. Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J Virol 2000, 74:4999-5005.
67. Colombo MJ, Sun G, Alugupalli KR. T-cell-independent immune responses do not require Cxc ligand 13-mediated B1 cell migration. Infect Immun 2010, 78:3950-3956.
68. Balázs M, Martin F, Zhou T, Kearney JF. Blood dendritic cells interact with splenic marginal zone b cells to initiate T-Independent Immune Responses. Immunity 2002, 17:341-352.
69. Saifer MG, Williams LD, Sobczyk MA, Michaels SJ, Sherman MR. Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins. Mol Immunol 2014, 57:236-246.
70. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110:103-111.
71. Verhoef JJ, Carpenter JF, Anchordoquy TJ, Schellekens H. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today 2014, 19:1945-1952.
72. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006, 8:R12.
73. Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther 2014, 16:R63.
74. Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther 2014, 16:R60.
75. Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J Control Release 2009, 137:234-240.
76. Oussoren C, Storm G. Effect of repeated intravenous administration on the circulation kinetics of poly(ethyleneglycol)-liposomes in rats. J Liposome Res 1999, 9:349-355.
77. Goins B, Phillips WT, Klipper R. Repeat injection studies of technetium-99m-labeled PEG-liposomes in the same animal. J Liposome Res 1998, 8:265-281.
78. Tagami T, Nakamura K, Shimizu T, Yamazaki N, Ishida T, Kiwada H. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. J Control Release 2010, 142:160-166.
79. Nagao A, Abu Lila AS, Ishida T, Kiwada H. Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application. Int J Pharm 2013, 441:395-401.
80. Cui J, Li C, Wang C, Li Y, Zhang L, Zhang L, Yang H. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase. J Pharm Pharmacol 2008, 60:1651-1657.
81. Koide H, Asai T, Kato H, Ando H, Shiraishi K, Yokoyama M, Oku N. Size-dependent induction of accelerated blood clearance phenomenon by repeated injections of polymeric micelles. Int J Pharm 2012, 432:75-79.
82. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of PEGylated liposomal doxorubicin. Clin Pharmacokinet 2003, 42:419-436.
83. Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 1984, 74:36-39.
84. Tillmann H, Ganson NJ, Patel K, Thompson AJ, Abdelmalek M, Moody T, McHutchison JG, Hershfield MS. High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hepatitis C (HCV) patients which is not associated with impaired response to PEG-interferon. J Hepatol 2010, 52:S129.
85. Longo N, Harding CO, Burton BK, Grange DK, Vockley J, Wasserstein M, Rice GM, Dorenbaum A, Neuenburg JK, Musson DG, et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet 2014, 384:37-44.
86. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56:1021-1028.
87. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed 2010, 49:6288-6308.
88. Armstrong JK, Leger R, Wenby RB, Meiselman HJ, Garratty G, Fisher TC. Occurrence of an antibody to poly(ethylene glycol) in normal donors. Blood 2003, 102:556.
89. Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 1992, 89:1643-1651.
90. Sundy JS, Baraf HSB, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, White WB, Lipsky PE, Horowitz Z, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. JAMA 2011, 306:711-720.
91. Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 2013, 30:1729-1734.
92. Chen D, Liu W, Shen Y, Mu H, Zhang Y, Liang R, Wang A, Sun K, Fu F. Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid derivative on ABC phenomenon. Int J Nanomedicine 2011, 6:2053-2061.
93. Abeles AM. PEG-ing down (and preventing?) the cause of pegloticase failure. Arthritis Res Ther 2014, 16:112.
94. Cavadas M, Gonzalez-Fernandez A, Franco R. Pathogen-mimetic stealth nanocarriers for drug delivery: a future possibility. Nanomedicine 2011, 7:730-743.
95. Abu Lila AS, Nawata K, Shimizu T, Ishida T, Kiwada H. Use OF POLYGLYCEROL (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int J Pharm 2013, 456:235-242.
96. Ishihara T, Maeda T, Sakamoto H, Takasaki N, Shigyo M, Ishida T, Kiwada H, Mizushima Y, Mizushima T. Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules 2010, 11:2700-2706.
97. Soshee A, Zürcher S, Spencer ND, Halperin A, Nizak C. General in vitro method to analyze the interactions of synthetic polymers with human antibody repertoires. Biomacromolecules 2013, 15:113-121.
98. Specht C, Schlüter B, Rolfing M, Brüning K, Pauels H-G, Kölsch E. Idiotype-specific CD4 + CD25+ T suppressor cells prevent, by limiting antibody diversity, the occurrence of anti-dextran antibodies crossreacting with histone H3. Eur J Immunol 2003, 33:1242-1249.
99. Moghimi SM. Re-establishing the long circulatory behaviour of poloxamine-coated particles after repeated intravenous administration: applications in cancer drug delivery and imaging. Biochim Biophys Acta Gen Subjects 1999, 1472:399-403.